Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 31, 2023
Expiration Date: March 31, 2024
Description:
Chimeric antigen receptor (CAR) T-cell therapy has led to remarkable response rates in eligible patients with B-cell hematologic malignancies. CD19 was chosen as the initial target tumor antigen for CARs because of its selective expression on B cells; however, researchers are currently investigating other targets, the potential of allogeneic CAR T therapy, and the use of combination therapies including dual CAR T-cell therapy and the addition of bispecifics in order to further improve the efficacy of CAR T-cell therapy and its availability to more patients.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the preconference CAR T workshop, held at the 27th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma in February 2023. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing hematologic malignancies in patients who may be eligible for CAR T therapy, putting recent clinical trial data into context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Describe the mechanism of action and specificities of CAR T cells and bispecific agents
• Integrate clinical data from landmark trials evaluating CAR T cells and bispecific agents in hematological malignancies
• Identify strategies to mitigate and manage toxicities associated with CAR T cells and bispecific agents in patients with hematological malignancies
• Discuss the therapeutic implications of emerging clinical data on CAR T cells and bispecific agents within the context of evolving treatment paradigms for hematological cancers.
